Open Access

Development of fever following first administration of zoledronate as a prognostic factor in advanced non‑small cell lung cancer patients with bone metastases

  • Authors:
    • Hiroki Izumi
    • Tadashi Igishi
    • Akira Yamasaki
    • Kennichi Takeda
    • Masaaki Yanai
    • Natsumi Tanaka
    • Tomohiro Sakamoto
    • Shizuka Nishii‑Ito
    • Hirokazu Touge
    • Masahiro Kodani
    • Shingo Matsumoto
    • Yuji Kawasaki
    • Eiji Shimizu
  • View Affiliations

  • Published online on: October 10, 2017     https://doi.org/10.3892/mco.2017.1447
  • Pages:1000-1004
  • Copyright: © Izumi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: PDF 0 views | HTML 0 views
0

Abstract

Nitrogen‑containing bisphosphonates (N‑BPs), which are usually used for the treatment of advanced cancer with bone metastasis, occasionally cause fever following the first administration. However, it is unclear as to how the development of fever following the first administration of N‑BP is associated with clinical outcome. The aim of the present study was to determine the prognostic value of the development of fever following the first administration of N‑BP in advanced non‑small cell lung cancer patients with bone metastases. The present study reviewed the data of 46 patients with advanced non‑small cell lung cancer who were administered zoledronate (ZOL), an N‑BP, for bone metastasis, between March 2009 and March 2011 in the Department of Medical Respirology at Tottori University Hospital. Clinicopathological factors were evaluated using univariate and multivariate analyses, and these factors were compared between the fever and non‑fever groups. Of the 46 patients, 15 (32.6%) developed fever following the first administration of ZOL. No significant differences were observed in the clinicopathological characteristics between the two groups. The overall survival in the fever group was significantly longer compared with the non‑fever group (median survival time: 33.4 vs. 15.7 months, P=0.04), and the development of fever following the first ZOL administration was independently associated with longer overall survival. The development of fever following the first ZOL administration was an independent prognostic factor in advanced non‑small cell lung cancer patients with bone metastases. Thus, ZOL‑associated fever may be a predictive factor for an undefined, survival‑promoting effect of ZOL.

Related Articles

Journal Cover

December 2017
Volume 7 Issue 6

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Izumi, H., Igishi, T., Yamasaki, A., Takeda, K., Yanai, M., Tanaka, N. ... Shimizu, E. (2017). Development of fever following first administration of zoledronate as a prognostic factor in advanced non‑small cell lung cancer patients with bone metastases. Molecular and Clinical Oncology, 7, 1000-1004. https://doi.org/10.3892/mco.2017.1447
MLA
Izumi, H., Igishi, T., Yamasaki, A., Takeda, K., Yanai, M., Tanaka, N., Sakamoto, T., Nishii‑Ito, S., Touge, H., Kodani, M., Matsumoto, S., Kawasaki, Y., Shimizu, E."Development of fever following first administration of zoledronate as a prognostic factor in advanced non‑small cell lung cancer patients with bone metastases". Molecular and Clinical Oncology 7.6 (2017): 1000-1004.
Chicago
Izumi, H., Igishi, T., Yamasaki, A., Takeda, K., Yanai, M., Tanaka, N., Sakamoto, T., Nishii‑Ito, S., Touge, H., Kodani, M., Matsumoto, S., Kawasaki, Y., Shimizu, E."Development of fever following first administration of zoledronate as a prognostic factor in advanced non‑small cell lung cancer patients with bone metastases". Molecular and Clinical Oncology 7, no. 6 (2017): 1000-1004. https://doi.org/10.3892/mco.2017.1447